Emergency Pod! uBiome: Anatomy of an Alleged Fraud with Wall Street Journal reporter Amy Dockser Marcus | E1192

Episode Summary

Executive Summary: This episode of This Week in Startups analyzes the UBiome fraud case, where former co-executives were charged with healthcare and securities fraud for misleading investors, filing fraudulent insurance claims, and falsifying medical records. Host Jason Calacanis interviews Wall Street Journal reporter Amy DoxerMarcus about the company's rise from citizen science to a $600 million valuation and its collapse. The discussion highlights parallels to Theranos, the role of charisma in startup culture, and failures in investor diligence.

Main Topics: UBiome's Rise and Fall (Priority: 5/5): From a 2013 citizen science Kickstarter to a $600 million valuation, UBiome ended in bankruptcy after an FBI raid and federal indictment for healthcare and securities fraud. Fraud Allegations (Priority: 5/5): Founders allegedly misled investors about revenue, cashed out $12M in secondary sales, filed $300M in fraudulent insurance claims ($35M reimbursed), and submitted fake doctor chart notes to justify tests. Comparison to Theranos (Priority: 4/5): Both cases involve charismatic founders, Stanford connections, TEDMed presentations, Wall Street Journal investigations, and systemic fraud. Calacanis notes parallels including romantic relationships between founders and deceptive practices. Investor Diligence Failures (Priority: 4/5): Calacanis criticizes venture firms for inadequate due diligence, noting UBiome's investors included Andreessen Horowitz, 8VC, and Slow Ventures. The discussion emphasizes how charisma and social proof can mask deception. Healthcare Fraud Mechanics (Priority: 3/5): UBiome exploited telemedicine gaps by using online doctors who approved tests without proper patient interaction, then falsified medical records when insurers requested documentation. The company also used dubious patient assistance programs to avoid patient copays. Citizen Science vs. Clinical Validation (Priority: 3/5): The company started as citizen science but transitioned to clinical claims without proper validation. DoxerMarcus explains the ethical and regulatory challenges of moving from self-experimentation to insurance-reimbursed medical tests. Journalism's Role in Exposing Fraud (Priority: 3/5): Calacanis praises the Wall Street Journal's investigative reporting, highlighting the resources required for such coverage and its importance in uncovering fraud before regulatory action.

Key Arguments: UBiome's founders built credibility through crowdfunding, Y Combinator, and prestigious investors, but systematically deceived stakeholders across multiple fronts - investors, insurers, patients, and doctors. Charismatic founders can use social proof techniques (TED talks, media coverage, prestigious partnerships) to mask fraud. Calacanis argues this pattern is common in startup culture. Investor due diligence failures enabled the fraud to continue through multiple funding rounds. Calacanis suggests VCs must talk to customers and verify claims more rigorously. The transition from citizen science to clinical testing requires rigorous proof that UBiome lacked. DoxerMarcus emphasizes the higher bar for insurance reimbursement vs. consumer self-payment. Telemedicine without proper doctor-patient relationships creates fraud vulnerabilities. UBiome exploited this by having doctors approve tests without meaningful consultations.

Data Points: Crowdfunding raised: $350,000 - UBiome raised this amount on Kickstarter/Indiegogo in 2013 to start their citizen science microbiome testing project. Total insurance claims filed: $300 million - UBiome allegedly submitted fake claims to insurers for tests that weren't validated or medically necessary. Insurance reimbursements received: $35 million - Despite $300M in claims, UBiome only received $35M in actual reimbursements, but this still represents significant fraud. Secondary stock sales by founders: $12 million - The founders cashed out $12 million in secondary sales to investors while allegedly misrepresenting revenue numbers. Series C valuation: $600 million post-money - UBiome raised $83 million in Series C funding in September 2018 at a $600 million valuation, shortly before the fraud was exposed. Court document length: 33 pages - The federal grand jury indictment in San Francisco was 33 pages long, detailing multiple charges of healthcare and securities fraud. Years from founding to collapse: 6 years - UBiome was founded in 2013 and filed for bankruptcy in September 2019 after the FBI raided offices in April 2019.

Pivotal Quotes: "The level of energy that went into trying to persuade people that what they were doing was real... if you really want to deceive people, I mean, a lot of energy went into deceiving investors and everyone else." — Amy DoxerMarcus: Commenting on the extensive efforts UBiome founders made to maintain the facade, including lying to doctors, patients, and insurance companies simultaneously. "They told the doctors one thing, they told patients another thing. They lied to the insurance companies." — Amy DoxerMarcus: Summarizing the multi-layered deception where different stakeholders received different false narratives about the company's operations. "In an email correspondence with a reporter, Jessica lied about her age, and she told the reporters that she was under 40 years old... it's important in building a narrative for investors and for others that you're young, you're cutting edge." — Amy DoxerMarcus: Detailing how founder Jessica Richman fabricated details about her age to appear on 'under 40' lists and build a specific narrative for investors. "They had supposed customer testimonials, photos, and then quotes from people who claimed to have benefited from taking their tests. And we did a story on how the photos were from Shutterstock." — Amy DoxerMarcus: Revealing that UBiome used stock photography for customer testimonials, demonstrating the pattern of fabricated social proof. "When you think about grifters and the techniques they use, one of the great techniques is the proximity to power, celebrity, or notability." — Jason Calacanis: Calacanis explains how fraudsters leverage social proof through association with legitimate institutions, celebrities, or media coverage to build false credibility.

Implications: This case underscores systemic failures in startup governance and investor diligence. Founders must be flagged that aggressive growth tactics can cross into criminal fraud. For investors, it signals need for rigorous clinical validation in health-tech and verification of revenue claims. The healthcare system remains vulnerable to billing fraud through telemedicine loopholes. Regulatory scrutiny of digital health startups will likely intensify.